|
· Marsha Aisyah · Bertha Verdina
On 28 August 2026, the Indonesian Constitutional Court, through Decision No. 255/PUU-XXIII/2025, restored the substance of Article 4(f) of Law No. 13 of 2016 on Patents, as amended by Law No. 65 of 2024. The decision restores the statutory exclusion of certain new uses of existing and/or known products and certain new forms of existing compounds from patent protection. While the provision is not limited to the pharmaceutical sector, the decision is particularly relevant to pharmaceutical patent protection, including patents relating to second medical use and new forms of known pharmaceutical compounds. Evergreening in Pharmaceutical Patents A patent grants exclusive rights to an inventor or patent holder over an invention for a certain period of time. In the pharmaceutical field, such protection plays an important role because the development of new medicines requires extensive research and significant investment. In return, the patent system provides a period of exclusivity so that inventors or companies developing medicines can obtain economic benefits from the results of their innovations. Under Law No. 13 of 2016 on Patents, a standard patent is granted for a period of 20 years from the filing date, while simple patents receive 10 years of protection. There is no mechanism to simply extend a patent after its term of protection has expired. The issue subsequently known as evergreening arises through a different mechanism. Evergreening essentially refers to efforts to obtain additional patent protection for an existing product, for example through the development of formulations, changes in methods of administration, combinations of active ingredients, or new therapeutic uses. Such additional patents may allow a patent holder to maintain commercial exclusivity over the same product or a related product even when the original patent is approaching the end of, or has reached the end of, its term of protection. Article 4(f) and the 2024 Amendment Prior to the amendment through Law No. 65 of 2024, Article 4(f) of Law No. 13 of 2016 specifically excluded the following from the definition of an invention: “discoveries in the form of: 1. new uses for existing and/or known products; and/or 2. new forms of existing compounds that do not result in a significant increase in efficacy and have related differences in chemical structure from the compound that is already known.” However, through Law No. 65 of 2024, paragraph (f) of Article 4 was deleted. As a result, these express exclusions were removed from Article 4 of the Patent Law. Constitutional Court Decision No. 255/PUU-XXIII/2025 On 28 August 2026, the Constitutional Court partially granted the petition in Case No. 255/PUU-XXIII/2025 and declared the word “dihapus” (“deleted”) in Article 4(f), as amended by Law No. 65 of 2024, to be contrary to the 1945 Constitution and to have no binding legal force, subject to the interpretation that Article 4(f) excludes the following from patent protection: (i) new uses for existing and/or known products; and/or (ii) new forms of existing compounds that do not result in a significant increase in efficacy and have related differences in chemical structure already known from the compound. The Court considered the provision important in preventing patent evergreening, particularly in the pharmaceutical sector, and in supporting access to affordable medicines and the generic pharmaceutical industry. The Court also restored the relevant Elucidation of Article 4(f) under Law No. 13 of 2016, which provides, among other things, clarification of the meaning of “existing and/or known products” and the concept of a “significant” increase in efficacy in the pharmaceutical field. Implications for Pharmaceutical Patents The decision is particularly relevant to pharmaceutical patent applications involving new therapeutic uses (second medical use), new forms of known compounds, and other developments relating to existing pharmaceutical products. Importantly, the decision does not mean that all modifications of existing pharmaceutical products are unpatentable. The exclusion specifically concerns the subject matter covered by Article 4(f), while inventions falling outside those exclusions must still be assessed against the applicable patentability requirements under the Patent Law. Primary Source: Constitutional Court Decision No. 255/PUU-XXIII/2025.
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
IP Blogby globomark ip M I T R ASejak 2011, kami aktif sebagai salah satu narasumber yang khusus menjawab pertanyaan-pertanyaan di bidang HKI bagi pengunjung situs www.hukumonline.com.
Lihat arsip tanya jawab HKI kami di Klinik Hukumonline, di sini. A R C H I V E S
October 2026
|
RSS Feed